Novagali Pharma Presents Phase III Clinical Trial of Vekacia(R) for Vernal Keratoconjunctivitis
Novagali Pharma, an emerging pharmaceutical company specialized in ophthalmology presents positive results of its pivotal phase III clinical trial positive results from the Phase III clinical study of
Vekacia(R) in children suffering from Vernal Keratoconjunctivitis (VKC) at the XIV Afro-Asian Congress of ophthalmology (AACO) held from June 20 to 25 2007 in Marrakech (Morocco). VKC...
Novagali Pharma Presents at AACO the Results of its Pivotal Phase
III Clinical Trial of Vekacia in Children Suffering From Vernal
Keratoconjunctivitis
EVRY, France, June 25, 2007 /PRNewswire/ -- Novagali Pharma, anemerging pharmaceutical company specialized in ophthalmologypresents positive results of its pivotal phase III clinical trialpositive results from the Phase III clinical study of
Vekacia(R) inchildren suffering from Vernal Keratoconjunctivitis (VKC) at theXIV Afro-Asian Congress of ophthalmology (AACO) held from June 20to 25...
Novagali Pharma Announces Positive Vekacia Clinical Results From
Pivotal Phase III Trial in Vernal Keratoconjunctivitis
EVRY, France, April 04, 2007 /PRNewswire/ -- Novagali Pharma, anemerging ophthalmic pharmaceutical company specialized inophthalmology, announces today positive results from the Phase IIIclinical study of
Vekacia(R) in children suffering from VernalKeratoconjunctivitis (VKC). In this orphan disease, it was shownthat both symptoms and signs of disease improved in patientsreceiving
Vekacia...